Intec Pharma is followed by the analysts listed above. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. Cantor Fitzgerald analyst Eliana Merle initiated coverage of Alexion with a Neutral rating and $121 price target. earnings-and-revenue-growth. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN) Today, Guggenheim initiated coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) with a Neutral. Apply today for this QC Micro Analyst (Fixed-term contract) job in Dublin with Alexion ... At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. Scott Henry Roth Capital Partners. Revenue (MM, USD) 2018. PharmaVitae explores Alexionâs prescription pharmaceutical performance and outlook over 2019â29. As consideration for these assets, Alexion received shares of Inozymeâs preferred stock representing a single-digit ownership percentage on a fully diluted basis. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more. The analysts of Bernstein have rated Alexion Pharmaceuticals with a Market Perform rating. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alexion Pharm's headlines and news coverage ⦠Analyst Coverage Analyst Coverage Ram Selvaraju HC Wainwright . Analyst Coverage Consensus Recommendations Alexion participates in E-Verify process. According to analysts' consensus price target of $155.00, Alexion Pharmaceuticals has a forecasted upside of 2.3% from its current price of $151.45. Analyst Coverage Achillion Pharmaceuticals is covered by the following analysts. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today a collaboration and license agreement that enables Alexion to use Halozymeâs ENHANZE ® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. Sell. Michael Higgins Ladenburg Thalmann . In a report issued on September 26, William Blair also initiated coverage with a ⦠A Different Perspective. Headquartered in Boston, Massachusetts, Alexion Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes life-transforming therapeutic products.As a leader in rare disease therapies for more than 25 years, the company has developed and commercializes two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria ⦠Analyst Ratings are available for US and Canadian equities. JMP Securities. On January 31, RBC Capital analyst Kennen MacKay reinstated coverage of Alexion with an Outperform rating and $135 price target. Liisa Bayko Leerink Swann. ... Achillion has been acquired by Alexion Pharmaceuticals, Inc. For ⦠Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN) Today, Raymond James initiated coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform with a price target of $161.00. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion ⦠Then again, Alexion analysts over the weekend suggested that their company could be worth more than the $175 per share being offered by Astra. In a report issued on November 12, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $125.00 price target. The analyst expects multiple re-ratings for the company in ⦠Jason McCarthy Maxim Group . A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALXN, but not buy more shares or sell existing shares. The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio â but analysts are struggling to see the match with Alexion⦠Because Alexion will be acquired by AstraZeneca, I am ceasing coverage. ... 18 analysts. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) â Investment analysts at Jefferies Financial Group upped their Q4 2019 earnings per share estimates for shares of Alexion Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 15th.Jefferies Financial Group analyst E. Yang now expects that the biopharmaceutical company will post earnings of $2.58 per ⦠A news analyst looks at the history of Alexion Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. Alexion Pharmaceuticals ALXN. Amount of Analyst Coverage Alexion Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst ⦠Joseph Schwartz Achillion Pharmaceuticals is followed by the analysts listed above. Alexion Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. The price target was set to $ 148.00. The acquisition includes Alexionâs patent estate, preclinical data, and manufacturing research relating to Alexionâs prior ENPP1 deficiency program. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. Analyst Conference Summary: Biotechnology. Overview â Alexionâs rare diseases portfolio maintains its solid growth and attractive orphan drug potential. conference date: February 4, 2021 @ 5:00 AM Pacific Time for quarter ending: De1ember 30, 2020 (fourth quarter 2020, Q4) Homology Medicines - Get Report rose after H.C. Wainwright analyst Patrick Trucchio took over coverage on the genetic medicines company and kept a ⦠The agreement provides Alexion with the opportunity for exclusive development of up to ⦠Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $152.67, which is a 42.9% upside from current levels. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors will be delighted, with the company turning in some strong numbers with its latest results.Results were good overall, with revenues beating analyst predictions by 2.0% to hit US$1.3b. Baird assumed coverage and downgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Outperform to Neutral with a price target of $170.00 (from $221.00). The stock has a consensus analyst rating of "Hold." The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $162.60 average price target, implying a 64.0% upside from current levels. 4.1K. Alexion Pharmaceuticals (ALXN) analyst call summary Q3 2020. Alexion Pharmaceuticals currently has 16 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. Alexion Pharmaceuticals Inc. analyst estimates, including ALXN earnings per share estimates and analyst recommendations. Earnings per share (EPS) came in at US$2.08, some 6.7% above what analysts had expected. Buy. Snapshot. Alexion Pharmaceuticals stock price prediction is an act of determining the future value of Alexion Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Alexion Pharmaceuticals stock future price could yield a significant profit. Hold. Alexion Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. At a current price of $ 150.10 there is downside potential of ⦠Still, EvaluatePharmaâs consensus-derived risk-adjusted NPV of Alexion product offering comes in about $10bn short of the $39bn takeover price, backing the suggestion that the UK group was overpaying.